Infertility and Sexual Health — Cost, Top Hospitals & Success Rates | MyMedicPlus

Infertility is defined as the failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse. The World Health Organization (WHO) estimates that approximately 17.5% of adults worldwide — roughly 1 in 6 people — experience infertility at some point in their reproductive lives, making it a major global health concern. When the female partner is aged 35 or older, investigation is recommended after just 6 months, reflecting the accelerating decline in ovarian reserve and oocyte quality with advancing maternal age.

Infertility and sexual health are deeply interconnected. Sexual dysfunction — including erectile dysfunction (ED) in men, vaginismus or dyspareunia in women, loss of libido in both partners — can directly impair fertility by reducing coital frequency or making intercourse impossible. Conversely, the psychological burden of infertility diagnosis and treatment frequently causes or exacerbates sexual dysfunction, creating a reinforcing cycle of distress. Sexually transmitted infections (STIs), particularly Chlamydia trachomatis and Neisseria gonorrhoeae, cause tubal damage and pelvic inflammatory disease (PID) that are leading preventable causes of tubal factor infertility.

The causes of infertility are roughly equally distributed between male factors (30–40%), female factors (30–40%), combined male and female factors (20–30%), and unexplained infertility (10–15%). This distribution underscores the importance of investigating both partners simultaneously from the outset. Infertility investigation and treatment are available to single individuals and same-sex couples through donor gamete pathways, and modern reproductive medicine increasingly adopts inclusive, person-centred care frameworks that acknowledge diverse family structures.

The psychological impact of infertility — encompassing grief, identity challenges, relationship strain, and the financial and physical burden of treatment — is now recognised as a significant health burden in its own right. Integrated care models that couple medical treatment with psychosexual counselling and peer support achieve superior patient experience and, in some studies, improved treatment outcomes.

A systematic assessment of both partners identifies the underlying cause in 80–85% of couples presenting with infertility.

Male Factor Infertility

Evaluated principally by semen analysis, which should be performed according to the WHO 2021 Laboratory Manual reference values: sperm concentration ≥16 million/mL, total sperm count ≥39 million, total motility ≥42%, progressive motility ≥30%, morphology (Kruger strict criteria) ≥4% normal forms. Abnormalities are classified as oligospermia (low count), asthenospermia (poor motility), teratospermia (abnormal morphology), or combined OAT syndrome. Azoospermia (complete absence of sperm) affects 1% of men and may be obstructive (post-vasectomy, congenital bilateral absence of vas deferens/CBAVD, epididymal obstruction) or non-obstructive (primary testicular failure, Klinefelter syndrome 47,XXY, Y-chromosome microdeletions in AZFa/AZFb/AZFc regions).

Female Factor — Ovulatory Dysfunction

Ovulatory disorders account for 25–30% of female infertility. WHO classification identifies three categories: Group I (hypogonadotrophic hypogonadism — hypothalamic amenorrhoea from weight loss, excessive exercise, or stress; responds well to gonadotrophin stimulation); Group II (normogonadotrophic anovulation — polycystic ovary syndrome/PCOS, which affects 6–10% of women of reproductive age and is the commonest single cause of anovulatory infertility); Group III (hypergonadotrophic hypogonadism — premature ovarian insufficiency, diminished ovarian reserve, post-chemotherapy, chromosomal e.g. Turner syndrome 45,X).

Tubal Factor and Pelvic Inflammatory Disease

Tubal occlusion or pelvic adhesions affect 20–25% of infertile women. The primary cause is PID from ascending genital tract infection, most commonly chlamydia or gonorrhoea. A single episode of PID results in tubal factor infertility in approximately 12% of women; three episodes raise this to over 50%. Assessment is by hysterosalpingography (HSG) or hysterosalpingo-contrast sonography (HyCoSy); diagnostic and operative laparoscopy with chromopertubation remains the gold standard.

Endometriosis

Affects 10–15% of women of reproductive age and 25–40% of infertile women. The mechanism of infertility in endometriosis is multifactorial: distorted pelvic anatomy from adhesions (in advanced stages III–IV), impaired folliculogenesis and oocyte quality, toxic peritoneal environment with elevated inflammatory cytokines, and implantation failure from altered endometrial receptivity. Surgical treatment of minimal-mild endometriosis modestly improves spontaneous pregnancy rates (ENDOCAN-1 trial). IVF is the primary treatment for moderate-severe endometriosis-associated infertility.

Uterine Factors

Intrauterine pathologies — submucous fibroids (Type 0, 1, 2), endometrial polyps, intrauterine adhesions (Asherman syndrome post-curettage or endometritis), and congenital uterine anomalies (septate uterus, unicornuate, bicornuate) — impair implantation and contribute to recurrent pregnancy loss. Assessment by 3D transvaginal ultrasound, saline infusion sonography, or hysteroscopy is recommended in the infertility workup.

Sexual Health Conditions Affecting Fertility

Erectile dysfunction prevents or reduces intercourse frequency and may reflect underlying systemic disease (diabetes, cardiovascular disease, hypogonadism) or psychological causes. Vaginismus (involuntary vaginal muscle spasm) and dyspareunia make penetrative intercourse impossible or painful, directly causing infertility independent of any reproductive pathology. Both conditions require dedicated psychosexual therapy, often with significant benefit, before or alongside assisted conception.

Infertility investigation and treatment eligibility is guided by clinical criteria, age, reproductive history, and — in publicly funded systems — additional criteria such as partner status, existing children, BMI, and smoking status. National eligibility criteria vary considerably between countries and health systems.

• When to begin investigation: Couples under 35 should seek investigation after 12 months of regular (at least 2–3 times weekly), unprotected sexual intercourse. Women aged 35–39 should seek assessment after 6 months. Women aged 40 or above, or any person with known risk factors for infertility (prior PID, PCOS, endometriosis, orchitis, chemotherapy, one or no testes) should seek immediate assessment without delay.
• Initial investigations: For both partners simultaneously. Male partner: semen analysis (two samples, 2–7 days abstinence, WHO 2021 criteria). Female partner: day 2–5 FSH, LH, oestradiol, AMH (ovarian reserve); mid-luteal serum progesterone (day 21 in 28-day cycle) to confirm ovulation; transvaginal ultrasound (antral follicle count, uterine anatomy, ovarian morphology for PCOS); rubella and chlamydia serology; karyotype and thyroid function where indicated.
• NHS (UK) eligibility for IVF: NICE (CG156) recommends up to 3 full IVF cycles for women under 40 with primary infertility of 2+ years; reduced access for women aged 40–42 with good prognosis. Local Clinical Commissioning Groups may further restrict access.
• Same-sex couples and single parents: Same-sex female couples (both partners with ovaries) may access IUI with donor sperm as first-line treatment. Same-sex male couples require gestational surrogacy and either donor oocytes or oocytes from a surrogate. Single women may access donor insemination. Single men require surrogacy. Legal frameworks for donor conception and surrogacy vary widely by country and require specialist legal advice.
• Fertility preservation: Individuals facing gonadotoxic cancer treatment, gender-affirming hormone therapy, or premature ovarian insufficiency should be offered fertility preservation (oocyte or embryo cryopreservation; sperm banking; ovarian tissue cryopreservation) before treatment commences.

Treatment is tailored to the identified cause, duration of infertility, female age, and couple preferences. A stepped approach progresses from least to most invasive, though female age often dictates faster progression to more effective treatments.

Ovulation Induction (OI)

First-line for anovulatory infertility (WHO Group II/PCOS). Clomiphene citrate (50–150 mg days 2–6) achieves ovulation in 70–80% and pregnancy in 30–40% of PCOS patients over 6 cycles. Letrozole (aromatase inhibitor, off-label but widely used) is superior to clomiphene in PCOS (PPCOS II trial: 27.5% vs 19.1% live birth rate). Gonadotrophins (FSH or hMG injections) are used for clomiphene-resistant PCOS or WHO Group I hypogonadism, requiring ultrasound monitoring to prevent ovarian hyperstimulation syndrome (OHSS) and multiple pregnancy.

Intrauterine Insemination (IUI)

Involves placing washed, concentrated sperm directly into the uterine cavity around the time of ovulation, bypassing cervical mucus barriers. Success rate per cycle is 10–15% (natural cycle) to 15–20% (stimulated cycle). Indicated for mild male factor (motile sperm count after wash ≥5–10 million), unexplained infertility, cervical factor, and donor sperm (single women, same-sex couples). NICE recommends 6 IUI cycles before proceeding to IVF in unexplained or mild male factor infertility in women under 40.

In Vitro Fertilisation (IVF)

The standard treatment for tubal factor, moderate-severe male factor, failed IUI, endometriosis-associated infertility, and unexplained infertility of 2+ years. A standard IVF cycle involves controlled ovarian hyperstimulation (COH) with daily FSH injections for 10–14 days monitored by serial ultrasound; oocyte retrieval under ultrasound-guided transvaginal needle aspiration under sedation; laboratory insemination of mature oocytes; embryo culture to blastocyst (day 5–6); and transfer of one (elective single embryo transfer, eSET) or two embryos into the uterine cavity. Live birth rates per egg collection are approximately 32% for women under 35, 25% for women 35–37, 19% for women 38–39, and less than 10% for women over 42 using their own eggs (HFEA, 2023 data).

Intracytoplasmic Sperm Injection (ICSI)

A variant of IVF in which a single morphologically selected sperm is injected directly into the oocyte cytoplasm using a fine glass micropipette. ICSI is indicated for severe oligospermia (total motile count <5 million), complete asthenospermia, surgically retrieved sperm (from testicular biopsy — TESE/micro-TESE — or epididymal aspiration — PESA/MESA — in obstructive or non-obstructive azoospermia), severe teratospermia, previous failed or very low fertilisation on standard IVF, and all cases using cryopreserved sperm. Fertilisation rates with ICSI (70–80%) are equivalent to conventional IVF in non-male-factor cases.

Donor Gametes and Surrogacy

Donor sperm is used when the male partner has no retrievable sperm (non-obstructive azoospermia without viable sperm on micro-TESE), carries a serious inheritable genetic condition, or is absent (single women, same-sex female couples). Donor oocytes are used when the female partner has premature ovarian insufficiency, severely diminished ovarian reserve, chromosomal abnormalities affecting oocytes, or repeated IVF failure with poor oocyte quality. Gestational surrogacy (using the commissioning couple's or donor embryos carried by a surrogate) is the pathway for same-sex male couples and women without a uterus.

Sexual Health and Psychosexual Interventions

Erectile dysfunction is treated with phosphodiesterase-5 inhibitors (sildenafil, tadalafil) as first-line; penile injections (alprostadil), vacuum erection devices, and penile prosthesis for refractory cases. Vaginismus is treated with graduated vaginal trainers (dilators) combined with psychosexual therapy; success rates exceed 90% with dedicated therapy. Psychosexual counselling — addressing communication, intimacy, performance anxiety, and the depersonalisation of sex during fertility treatment — is recommended for all couples in fertility care and is associated with improved wellbeing and, in some evidence, improved treatment outcomes through reduced cortisol-mediated hypothalamic disruption.

Modern reproductive medicine achieves impressive outcomes, though success depends heavily on female age, cause of infertility, and duration of subfertility:

• IVF cumulative success: Over three complete IVF cycles (including frozen embryo transfers from each stimulation), cumulative live birth rates for women under 35 approach 60–70%, declining to 30–40% for women aged 35–39, and 15–25% for women aged 40–42. These figures, derived from large registry studies (HFEA, CDC ART data), are the most reliable guide for patient counselling.
• Donor oocyte IVF: When donor oocytes are used, live birth rates are largely determined by the donor's age and oocyte quality rather than the recipient's age, achieving 40–55% per transfer regardless of recipient age — a critical consideration for older women with diminished ovarian reserve.
• Male factor outcomes: ICSI has transformed outcomes for couples with severe male factor infertility who previously had no path to biological parenthood. For obstructive azoospermia (e.g., post-vasectomy), TESE-ICSI achieves live birth rates comparable to ejaculated sperm IVF. For non-obstructive azoospermia, micro-TESE retrieves viable sperm in 30–60% of cases depending on histology.
• Psychosexual intervention outcomes: Studies in vaginismus report complete resolution of penetrative intercourse difficulty in 85–95% of women completing a full graduated dilation programme with psychosexual support. ED treatment with PDE5 inhibitors achieves satisfactory erections in 60–80% of men with psychogenic or mixed ED.
• Endometriosis surgery: Surgical treatment of endometrioma before IVF modestly improves IVF outcomes in some studies, though pooled evidence (Cochrane 2021) does not support routine surgery before IVF. Operative laparoscopy for minimal-mild endometriosis (ENDOCAN-1, Canada) doubles the odds of spontaneous conception compared to diagnostic laparoscopy alone.

All fertility treatments carry specific risks that must be discussed transparently before treatment commences:

• Ovarian Hyperstimulation Syndrome (OHSS): A potentially serious complication of ovarian stimulation, characterised by enlarged ovaries, ascites, and in severe cases, thromboembolism and renal impairment. Mild-moderate OHSS affects 20–30% of IVF cycles; severe OHSS requiring hospitalisation occurs in 1–2%. OHSS risk is higher in PCOS patients and those with high antral follicle count. Strategies to reduce OHSS include GnRH antagonist protocols, GnRH agonist trigger instead of hCG trigger, elective embryo freeze-all, and use of cabergoline.
• Multiple pregnancy: Twin pregnancies are associated with significantly higher rates of preterm birth, low birthweight, perinatal mortality, and maternal complications compared to singleton pregnancies. Elective single embryo transfer (eSET) with cryopreservation of surplus embryos for subsequent frozen embryo transfers has reduced multiple birth rates in countries with mandatory or recommended eSET policies (HFEA UK: <10% in 2022).
• Miscarriage: The background miscarriage rate of 15–20% in natural conceptions increases with maternal age. Miscarriage rates following IVF are similar to those in naturally conceived pregnancies of the same age group. Recurrent miscarriage (3 or more consecutive losses) affects 1% of couples and warrants specific investigation (antiphospholipid antibody syndrome, thrombophilia, uterine anomaly, parental karyotype).
• Ectopic pregnancy: Risk is approximately 2–3% of IVF clinical pregnancies, higher than in natural conception (1.5–2%), particularly in women with tubal factor infertility.
• Oocyte retrieval risks: Bleeding (requiring transfusion in <1%) and infection (<0.5%) are rare. Injury to adjacent structures (bowel, blood vessels) is extremely rare (<0.1%) but may require surgical intervention.
• Psychological effects: Failed IVF cycles are associated with significant grief, depression, and relationship strain. Psychological support should be offered proactively rather than reactively. Couples who discontinue IVF before achieving pregnancy report the highest psychological morbidity.

Follow-up during active fertility treatment is intensive and involves both clinical monitoring and psychosocial support:

• During IVF stimulation: Serial transvaginal ultrasound monitoring every 1–3 days during stimulation to assess follicular response and endometrial development, with serum oestradiol measurement to guide dose adjustments and identify OHSS risk. Trigger injection (hCG or GnRH agonist) is timed when the leading follicles reach 17–18 mm diameter; oocyte retrieval follows 34–36 hours later.
• Post-transfer monitoring: Serum beta-hCG measured 14–16 days after oocyte retrieval (IVF) or insemination (IUI) to confirm pregnancy. Rising beta-hCG (doubling time 48 hours) followed by transvaginal ultrasound at 6–7 weeks to confirm intrauterine implantation and fetal heartbeat. Ectopic pregnancy must be excluded in cases of pain, bleeding, or slowly rising hCG.
• After successful conception: IVF pregnancies are managed as higher-risk obstetric cases (if there is a specific risk factor such as twins or advanced age) in conjunction with obstetric services. Progesterone luteal support (vaginal pessaries or injections) is continued until 12 weeks gestation.
• After unsuccessful treatment: A debrief consultation should be offered 4–6 weeks after a failed cycle to review the embryology report, discuss contributing factors, and plan the next steps. Psychological support should be actively offered. Natural conception can occur in the months after a failed IVF cycle, and couples should be counselled accordingly.
• Long-term follow-up of children born after ART: Children born after IVF/ICSI have equivalent developmental outcomes and health to naturally conceived children at population level. Imprinting disorders (Beckwith-Wiedemann syndrome, Angelman syndrome) are very slightly more common after ICSI, but absolute risk remains very low. Long-term offspring health registries continue to provide reassurance.

The cost of fertility treatment varies enormously by country, health system, clinic, and treatment type. In many countries, fertility treatment is largely or entirely self-funded:

• IUI: USD 300–1,500 per cycle (excluding medications) in most countries. Donor sperm adds USD 500–1,500 per vial. In publicly funded systems (NHS England), up to 6 IUI cycles may be funded; in private care, total costs per cycle including monitoring typically range from USD 800–2,500.
• IVF (self-funded, own eggs): USD 8,000–15,000 per cycle in the United States; USD 4,000–7,000 in the UK private sector; USD 2,000–6,000 in India, Spain, Czech Republic, and other medical tourism destinations. Medications add USD 1,500–4,000 per stimulation cycle. Embryo cryopreservation and annual storage fees add USD 500–2,000 annually.
• ICSI: Typically adds USD 1,000–2,000 to the cost of a standard IVF cycle.
• Donor egg IVF: USD 15,000–30,000 in the US including donor compensation; USD 5,000–12,000 in Spain, Czech Republic, and Greece where regulatory frameworks support affordable donor programs.
• Preimplantation Genetic Testing (PGT-A/PGT-M): Adds USD 3,000–6,000 to IVF costs; indicated for carriers of chromosomal translocations, single gene disorders, or recurrent miscarriage.
• Publicly funded access: Wide variation: NHS England funds up to 3 IVF cycles in some areas (often reduced to 1 locally). Nordic countries, Israel, and Belgium offer generous public funding. The US, Australia, and most of Asia require substantial self-funding.
• Medical tourism: Spain, Czech Republic, Greece, and Cyprus are major destinations for donor egg IVF at USD 5,000–12,000. India offers IVF from USD 1,500–4,000 per cycle at accredited clinics, attracting international patients.

Not all infertility requires assisted reproductive technology. Alternative and complementary pathways include:

• Expectant management and timed intercourse: For couples with unexplained infertility of short duration and young female age, 6–12 months of expectant management with optimised timed intercourse (confirmed by LH surge urine testing) yields spontaneous conception rates of 30–40% — comparable to IUI in this group — without the cost, inconvenience, or risks of intervention (NICE CG156).
• Surgical correction: Laparoscopic salpingostomy for unilateral distal tubal occlusion, resection of submucous fibroids (hysteroscopic myomectomy), septum resection (hysteroscopic metroplasty), or lysis of intrauterine adhesions may restore fertility without requiring ART in selected cases. The option of surgery vs direct IVF must be weighed against the female partner's age and ovarian reserve.
• Weight optimisation: BMI below 19 or above 30 significantly impairs both natural conception and IVF success. Weight loss in overweight women with PCOS restores spontaneous ovulation in up to 70%. Structured weight management programmes improve outcomes and reduce OHSS risk before IVF.
• Lifestyle modification: Smoking cessation improves oocyte quality and reduces IVF cancellation rates; heavy alcohol use adversely affects both male and female fertility; optimising male scrotal temperature (avoiding tight underwear, hot baths) may modestly improve sperm quality in oligospermia.
• Adoption and fostering: A legitimate and valuable pathway to parenthood for those who choose it or for whom medical treatment has been unsuccessful, adoption provides a child with a family and fulfils the desire for parenthood. Waiting times and eligibility criteria vary by country.
• Child-free living: For some individuals and couples, the decision to live without children — reached after careful reflection and often supported by counselling — is an outcome that fertility services should support and respect rather than pathologise.